Younger children are more responsive to amblyopia treatment

Article

Children aged 7 years and younger are more responsive to amblyopia treatment than those aged between 7 and 13 years.

Children aged 7 years and younger are more responsive to amblyopia treatment than those aged between 7 and 13 years, according to a study featured in Archives of Ophthalmology.

Dr Jonathon M. Holmes and his team, Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA, performed a meta-analysis of 4 recently completed randomized amblyopia treatment. This was done to evaluate the correlation between age and improvement in logMAR amblyopic eye visual acuity.

Each analysis was adjusted for spherical equivalent refractive error in the affected eye, type of amblyopia, baseline amblyopic eye visual acuity, previous amblyopia treatment, study treatment and protocol.

The results demonstrated that children aged between 7 and 13 years had a significantly reduced response rate to amblyopia treatment than children less than 7 years of age. However, no differences were found between those aged 3 to 5 years and those aged between 5 and 7 years with moderate ambylopia. Children aged between 3 to 5 years with severe ambylopia had a greater response to treatment than those aged 5 to 7 years.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.